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Complement activation and leukocyte stimulation were prospectively stud- 
ied during and after cardiopulmonary bypass in 16 children receiving 
sodium ni t ropruss ide- -a  nitrovasodilator releasing nitric oxide--for vaso- 
dilation during the cooling and rewarming periods of extracorporeal 
circulation. Results were compared with those in 29 patients who were not 
treated with sodium nitroprusside during the operation. Patients treated 
with sodium nitroprusside had significantly less C3 conversion during 
cardiopulmonary b pass as measured by the ratio C3d/C3 (p < 0.05) and 
significantly less C5a l iberation immediately after cardiopulmonary b pass 
(p < 0.005) than patients not treated with sodium nitroprusside. C4 was not 
overtly consumed in our series. Leukocyte count during the rewarming 
period of cardiopulmonary bypass, but not leukocyte elastase release 
during cardiopulmonary bypass, was significantly reduced in patients 
treated with sodium nitroprusside (p < 0.05). In  vitro experiments were 
conducted to analyze the effect of sodium nitroprusside on complement 
hemolytic activity init iated by the classic and the alternate pathways and on 
zymosan-induced C3 conversion by the activation of the alternate pathway. 
The in vitro experiments clearly demonstrate inhibition of complement 
hemolytic activity by sodium nitroprusside in the sera tested. The 50% 
inhibitory concentration of sodium nitroprusside on the available comple- 
ment hemolytic activity was less through the alternate pathway than 
through the classic one (4.2 - 0.8 mmol/L and 14.0 - 2.88 retool/L, 
respectively). The decrease of complement hemolytic activity measured was 
dose-dependent and was enhanced by the sodium nitroprusside preincuba- 
tion of the sera tested. This effect was related to the duration of preincu- 
bation. Sodium nitroprusside photodegradation (enhancing nitric oxide 
release) increased the anticomplementary effect of the drug, reducing the 
50% inhibitory concentration on complement hemolytic activity to 0.24 to 
0.02 mmol/L for the alternate pathway and 2.74 o 0.3 mmol/L for the classic 
pathway. The zymosan-induced C3 conversion was inhibited by sodium 
nitroprusside. Nitroglycerin and isosorbide dinitrate (other nitric oxide 
donors) had in vitro effects on complement hemolytic activity similar to 
those of nonphotodegraded sodium nitroprusside at similar concentrations 
(1 mmol/L). Our results suggest hat sodium nitroprusside, both in vitro 
and in vivo, has an inhibiting effect on complement activation init iated by 
both classic and alternate pathways and that this effect is mediated by 
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nitric oxide release from sodium nitroprusside. This is the first report on 
the anticomplementary effect of sodium nitroprusside by nitric oxide 
release. (J TItORAC CARDIOVASC SURG 1996;111:882-92) 
T he complex generalized inflammatory reaction resulting from cardiopulmonary bypass (CPB) 
involves the liberation of various humoral and intra- 
cellular mediators that could be related to the 
development of postoperative organ dysfunction, 
the pathophysiologic basis of which includes the loss 
of endothelial integrityJ' 2 Complement activation, 
by contact between blood and foreign surfaces and 
by its interactions with other biologic cascades, 3 is 
thought to play a central role in this inflammatory 
reaction.l, 4, 5 Complement anaphylatoxins C3a and 
C5a are potent leukocyte chemotactic factors, in- 
ducing leukocyte stimulation with proteolytic en- 
zyme and oxygen-derived free radical release and 
cytokine production, 5-12 which in turn may be in- 
volved in the development of postoperative organ 
injury.5, 9, 13, 14 Several therapeutic interventions 
have been proposed to prevent or limit the magni- 
tude of the inflammatory reaction occurring during 
CPB. These include nonspecific treatment with con- 
flicting clinical and experimental results such as, 
among others, the preoperative administration of 
corticosteroids, 15-t7 of the protease inhibitor apro- 
tinin, 1s-a° or of methylxanthine p ntoxifylline, which 
inhibits the inflammatory action of interleukin-1 and 
tumor necrosis factor-oe. 21' 22 A more specific ap- 
proach, the administration of human recombinant 
soluble complement receptor 1, which inhibits clas- 
sic, alternate, and terminal pathway activation of the 
complement cascade, was recently investigated in an 
animal model. 23 Because complement activation 
may play a central role in the CPB-induced inflam- 
matory reaction, the attenuation of complement 
activation makes this therapeutic approach rational. 
We here report the effect of sodium nitroprusside 
(SNP), a long known vasodilator 24 and nitric oxide 
donor, 25 on complement activation and leukocyte 
mobilization occurring during CPB. Inasmuch as 
our clinical observations suggested an in vivo inhib- 
itory effect of SNP on complement activation in- 
duced by CPB, we verified this hypothesis by in vitro 
experiments. We document for the first time the 
influence of this drug on both the alternate and the 
classic pathways of complement activation and dis- 
cuss its mechanism of action. 
Patients and methods 
Clinical. Sixteen infants and children aged 6 months to 
7 years (mean age 29 months) undergoing cardiac opera- 
tions for congenital cardiac defects were included in this 
prospective study. Diagnoses and types of surgical proce- 
dures are shown in Table I. These 16 patients were 
operated on at the same time as a group of 29 patients 
aged 3 months to 17 years (mean age 40 months) studied 
in the same way and reported on previously. 13The CPB 
protocol in both patient groups was identical with one 
exception: for vasodilation during the cooling and the 
rewarming periods of extracorporeal circulation, the 16 
patients tudied here received SNP systematically instead 
of phentolamine or they received no vasodilator at all. 
Anesthesia nd antibiotic regimen. Conventional general 
anesthesia was performed in all patients. Cefotiam hydro- 
chloride (25 mg/kg) and dexamethasone (3 mg/m a) given 
for prophylaxis of cerebral edema were administered 
before sternotomy. 
CPB. The CPB protocol was identical for the 16 children 
examined. A roller pump, a disposable membrane oxygen- 
ator, and an arterial filter were used. Cooling and rewarming 
were done with a heat exchanger. The priming solution 
consisted of a crystalloid solution, mannitol (3 ml/kg), and 
fresh whole blood. The hematocrit value of the circulating 
volume averaged 25%. CPB was instituted after right atrial 
or bicaval and aortic cannulation with a perfusion index of 
2.7 L/m 2. Heparinization was achieved with heparin sulfate 
(3 mg/kg). For vasodilation in the cooling period, all 16 
children received a continuous infusion of SNP (0.6 to 2.9 
txg/kg per minute, average 1.7 /xg/kg per minute). Aortic 
crossclamping was done and cardioplegia was induced by a 
single intraaortic injection of cold (4 ° C) Bretschneider 
solution (30 ml/kg). In 12 children, the operation was per- 
formed under deep hypothermia (nasopharyngeal tempera- 
ture averaging 16 ° C) and circulatory arrest. Low-flow CPB 
was conducted (perfusion index averaging 25% of the initial 
one) when circulatory arrest reached 60 minutes. The other 
four children were operated on with low-flow CPB (naso- 
pharyngeal temperature averaging 26 ° C). In all children the 
lungs were reventilated when core temperature ached 30 ° 
C and a continuous infusion of SNP was reinstituted at the 
beginning of rewarming (0.6 to 2.9 tzg/kg per minute, aver- 
age 1.6 txg/kg per minute). Anticoagulation during CPB was 
monitored by determination f activated clotting time. Hep- 
arin was neutralized with protamine sulfate (6 mg/kg) in- 
jected into the aorta. Catecholamines were administered if 
necessary for weaning the patients from CPB. 
Postoperative care. In the intensive care unit, sedation 
and analgesia were maintained with diazepam and morphine 
sulfate. The catecholamine and vasodilatory regimen was 
adapted to the particular hemodynamic situation. 
Beyond standard eterminations of blood gas and se- 
rum electrolyte values, laboratory tests including liver 
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Table I. Patient data 
Patient Age Surgical 
no. (too) Diagnosis procedure Complications Outcome 
1 6 Abnormal origin of LCA LCA reimplantation None Discharged 
2 12 VSDs, ASD VSD + ASD closure None Discharged 
3 2 LV tumor Tumor extirpation None Discharged 
4 12 Down, AVSD Repair None Discharged 
5 39 AoS, ASD Repair None Discharged 
6 54 TOF, ASD Repair None Discharged 
7 34 Down, VSD VSD closure PPS Discharged 
8 7 AVSD, MI Repair None Discharged 
9 11 Down, AVSD Repair None Discharged 
10 10 Down, AVSD Repair None Discharged 
11 16 D-TGA, ASD Senning None Discharged 
12 51 TOF, RVOT enlargement Repair attempt Died on operating 
RV failure table 
13 11 TOF Repair None Discharged 
14 47 Single ventricle, TGA, CoA Fontan modified MSOF Died 
CoA repair + PAB 
15 66 DORV, L-TGA, hypoplastic Fontan modified MSOF Died 
LV, sub-PS 
16 83 TGA, VSD; Senning, VSD VSD closure AVB III Discharged 
closure; sub@S, VSD LVOT enlargement PM 
LCA, Left coronary artery; VSD, ventricular septal defect;ASD, atrial septal defect; Down, Down syndrome;AVSD, atrioventricular septal defect;AoS, aortic 
stenosis; TOF, tetralogy ofFallot; MI, mitral insufficiency; TGA, transposition of the great arteries; RVOT, right ventricular outflow tract; RV, right ventricular; 
CoA, coarctation f the aorta; PAB, pulmonary artery banding; PS, pulmonary stenosis; PPS, postpericardiotomy syndrome; MSOF, multiple organ system 
failure; AVB, atrioventricular block; PM, pacemaker implantation. 
Table I I .  Sample time schedule 
6 
7 
8 
9 
10 
11 
Preoperative 
After heparin administration 
Ten minutes after onset of CPB 
Lungs reventilated 
Core temperature >30 °C 
After protamine administration 
First postoperative day (9:00 AM) 
Second postoperative day (9:00 AM) 
Third postoperative day (9:00 AM) 
Fifth postoperative day (9:00 AM) 
Seventh postoperative day (9:00 AM) 
enzyme and serum creatinine concentrations and coagu- 
lation times were routinely performed at least twice a day. 
Thiocyanate l vels were monitored if indicated. Multiple 
system organ failure was diagnosed on the basis of our 
previous definition. 13 
Collection of samples. Venous blood was collected be- 
fore and after the operation. During CPB blood was with- 
drawn from the arterial ine of the circuit. For each sample 
time, 2 ml of blood taken in tubes containing ethylenedia- 
minetetraacetic a id was necessary for analyzing comple- 
ment factors and 0.3 ml for leukocyte count and differenti- 
ation. The sample time schedule is shown in Table II. 
Determination of complement factors. The samples for 
complement analysis were immediately centrifuged for 3 
minutes (3000 rpm) and the plasma was stored at -70  ° C 
until analysis. 
C3 and C4 were determined by standard methods of 
turbidimetry 26 with the use of the immunoglobulin G 
faction of a rabbit antihuman C3 or C4 antiserum with an 
automated procedure on an RA 1000 turbidimeter (Tech- 
nicon, Brussels, Belgium). 
For C3d determination, the sample was incubated 
(volume/volume) with borate buffer containing 22% poly- 
ethylene glycol for 1 night at 4 ° C. After centrifugation to
discard the C3 molecules, the supernatant was analyzed by 
turbidimetry as described for C3 and C4 with the follow- 
ing modifications: the sample diluent was supplemented 
with 20% distilled water to allow a reduction of polyeth- 
ylene glycol to a maximum of 3.5% in the reaction mixture 
during immunoprecipitation. 
C5a was determined by enzyme immunoassay (Enzyg- 
nost C5a, Behring, Hoechst, Brussels, Belgium). Normal 
range for healthy adults is 0.15 to 0.45/xg/L. 
Elastase was measured with immunoactivation e zyme 
immunoassay (Merck, Darmstadt, Germany). Normal val- 
ues for healthy adults are 22 + 10/xg/L. 
Leukocyte count and differentiation were determined 
by a Coulter counter (Coulter Electronics, Inc., Hialeah, 
Fla.). Inasmuch as several individual factors such as 
postoperative catecholamine administration possibly in- 
fluence leukocyte count, circulating leukocytes were de- 
termined before CPB, during CPB, and after protamine 
administration, but not later. Leukocyte count was cor- 
rected for hemodilution according to the following for- 
mula: L c = L s × (Htc/Hts), where Lc = corrected leuko- 
cytes, L s = sample leukocytes, Ht c = control hematocrit, 
and Ht s = sample hematocrit. 
The other values determined uring CPB were not 
corrected for hemodilution, because we considered the 
measured concentrations to be biologically relevant. 
In vitro experimentation 
Experimental schedule. Sera taken from healthy blood 
donors from the "Centre Albert Hustin," Brussels, were 
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analyzed for complement hemolytic activity (CHs0) in the 
presence of increasing SNP concentrations (1 to 16 
mmol/L; molecular weight of SNP = 298). CHso also was 
measured after various periods of preliminary incubation 
(15, 30, 60, and 120 minutes) with a minimal active 
concentration of SNP (0.6 mmol/L). This was repeated 
after light degradation of SNP by ultraviolet exposure of 
the SNP solution for 20 minutes. The effect of SNP on 
zymosan-induced C3d generation and, finally, the effect of 
nitroglycerin and isosorbide dinitrate on CHso were also 
studied. 
CHso. The alternate pathway was evaluated with a 
quantitative microassay, with rabbit erythrocytes u ed as 
target cells in the presence of ethyleneglycoltetraacetic 
acid-Mg++-veronal ge atin dextrose buffer, in microtiter 
plates after six serial dilutions of serum samples. Hemo- 
lysis was measured with an MR 5000 microplate reader 
(Dynatech; van der Heyden, Brussels, Belgium) at 630 
nm, according to our previously described methods. 27 
The classic pathway was determined in the same man- 
ner as the alternate pathway with sheep erythrocytes 
sensitized with rabbit hemolysin in Ca++-Mg++-veronal 
gelatin dextrose buffer. 
Chemicals. SNP (Nipride, Roche), nitroglycerin (Nys- 
conitrine, Bio-Therabel), and isosorbide dinitrate (C6do- 
card, C6ocard, Byk Belga) solutions used were provided 
from the hospital pharmacy. Control solutions were pre- 
pared with ferrocyanide and potassium cyanide obtained 
from the laboratory (Merck, Belgolabo, Belgium) and the 
hospital pharmacy, respectively. 
Statistical analysis. Results are expressed in the text 
and in the tables by the mean value _+ standard eviation 
(SD) and in the figures by the mean _+ standard error of 
the mean (SEM). For analysis of time-dependent varia- 
tions of parameters within the same group, one-way 
analysis of variance for multiple comparisons with 
Scheffe's correction procedure was used. Comparisons of 
values between two groups in the clinical and experimen- 
tal studies were done with the nonparametric Mann-Whitney 
U test or the paired Wilcoxon test. The paired ttest was used 
for analysis of in vitro experiments on small series (n = 5). )(2 
Analysis was performed with Yates' correction for occa- 
sional low cell values. The data were computerized and 
analyzed with the SPSS software (SPSS Inc., Chicago, Ill.). 
All p values lower than 0.05 were considered significant. 
Resu l ts  
C l in ica l  resu l t s .  Clinical data of the 16 patients 
are shown in Table I. The results of the present 
study are described and briefly compared with the 
results of our previous work, 13 which are presented 
as our own reference values. 
Durations of CPB, aortic crossclamping, and cir- 
culatory arrest averaged 82 minutes (range 35 to 273 
minutes), 63 minutes (range 29 to 124 minutes), and 
48 minutes (range 6 to 59 minutes), respectively, and 
were identical to those of the previous group. 
One child (patient 12) could not be weaned from 
extracorporeal circulation and died on the operating 
table because of severe right ventricular failure. 
Multiple organ system failure developed in two 
children (patients 14 and 15) after modified Fontan 
procedures, and they died on the fifth and tenth 
postoperative days, respectively. Multiple organ sys- 
tem failure was less prevalent in the present study 
(2/16) than in the previous group (8/29), but this 
difference reached a significance level of only 0.1 
(1 - 2a; )(2 with Yates' correction). Postpericar- 
diotomy syndrome developed on the sixth postoper- 
ative day in one child. The other patients had no 
postoperative complications. 
Hematocrit values. Hematocrit values fell from a 
preoperative value of 42% + 11% (mean +_ SD) to 
28% _+ 5% 10 minutes after induction of CPB. The 
hematocrit values remained stable during CPB and 
reached normal preoperative values from the imme- 
diate postoperative period on according to our 
previous observations. 
Complement factors. All children had normal C3 
values before the operation (C3 = 121 _+ 25.5 
mg/dl) (mean _+ SD). C3 concentrations fell to 56 _+ 
12.5 mg/dl after induction of CPB and remained 
stable up to the end of CPB, after protamine 
administration (C3 = 67.8 + 12.7 mg/dl). C3 values 
rose slowly from the first postoperative day on and 
reached normal values on the fifth postoperative 
day, in accordance with our previous results. 
C3d/C3 was in the normal range before the oper- 
ation in all children (C3d/C3 = 0.75 ± 0.36) 
(mean _+ SD). C3d/C3 rose from a value of 0.61 + 
0.34 10 minutes after institution of CPB (sample 
time 3) to 1.10 _+ 0.45 after protamine administra- 
tion (sample time 6). C3 conversion during CPB was 
significant (p < 0.001). C3d/C3 reached normal 
values from the first postoperative day on (sample 
time 7) (C3d/C3 = 0.80 + 0.45) and remained 
within the normal range during the first postopera- 
tive week. C3 conversion after protamine adminis- 
tration was significantly lower in the current patient 
group than in the previous one (p = 0.02). This was 
also true of the difference between C3d/C3 mea- 
sured after protamine administration (sample time 
6) and initiation of CPB (sample time 3) (p = 0.02). 
Fig. 1 compares the course of C3d/C3 in the current 
patient group with that in the previous one. 
C4 was in the normal range before CPB in all 
children (C4 = 19.8 ± 8.35 mg/dl) (mean ± SD). 
After institution of CPB (sample time 3), the C4 
value fell to 9.53 ± 3.29 mg/dl. C4 remained stable 
during CPB up to the end of CPB, after protamine 
administration (sample time 6) (C4 = 11.4 _+ 3.5 
mg/dl). C4 reached preoperative values on the third 
postoperative day and remained in this range (sam- 
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Fig. 1. Course of C3d/C3 before, during, and after CPB in patients treated with SNP (interrupted line) 
(n = 16 until sample time 5, n = 15 until sample time 10, and n = 13 at sample time 11), and in patients 
not treated with SNP (solid line) (n = 29 until sample time 7, n = 27 at sample time 8, n = 26 until sample 
time 10, and n = 22 at sample time 11). Results are expressed by the mean _+ SEM. For sample time 
specification, see Table II. Asterisk indicates ignificant differences (p < 0.05) between the two groups 
(Mann-Whitney U test). 
ple time 9) (C4 = 15.1 __ 7.3 mg/dl). These results 
were identical to our previous results. 
Compared with normal values in healthy adults 
(C5a = 0.15 to 0.45 txg/L), C5a values were elevated 
in all children after protamine administration (sam- 
ple time 6) (C5a = 8.64 + 4.41 pog/L) (mean ± SD). 
They were significantly lower, however, than values 
reported in our reference group (C5a = 18 ± 11.8 
/xg/L) (p < 0.005). 
Leukocytes and neutrophils. Leukocyte count fell 
from a preoperative value of 6.83 + 2.26 × 109/L 
(mean _+ SD) to a value of 3.3 _+ 0.9 × 109/L 10 
minutes after induction of CPB (sample time 3) 
(p < 0.0001). Leukocyte counts remained stable 
during CPB but increased at the end of the rewarm- 
ing period (sample time 5) (leukocyte count = 3.7 ± 
3.3 × 109/L) (1) < 0.05), increasing significantly after 
protamine administration (sample time 6) (leuko- 
cyte count = 11.3 ± 5.9 × 109/L) (p < 0.0001). 
Leukocyte count after lung reventilation (sample 
time 4) and at the end of the rewarming period 
(sample time 5) was significantly ower than our refer- 
ence values (p < 0.02 andp < 0.05, respectively). 
Neutrophil counts fell from a preoperative value 
of 3.3 ± 2.3 × 109/L to 1.3 -+ 0.6 × 109/L at sample 
time 3 (p < 0.0001). Neutrophil counts remained 
stable during CPB but increased at the end of the 
rewarming period (sample time 5) (neutrophil 
count = 1.8 ± 2.6 × 109/L) (p < 0.05), increasing 
significantly after protamine administration (sample 
time 6) (neutrophil count = 7.8 ± 4.4 × 109/L) (p < 
0.0001). Neutrophil count after lung reventilation 
(sample time 4) was significantly lower than our 
reference values (p < 0.05). 
Leukocyte lastase. Leukocyte lastase rose in all 
children from 106 __ 59 /xg/L (mean - SD) 10 
minutes after institution of CPB (sample time 3) to 
418 _+ 244 /xg/L after protamine administration 
(sample time 6). These values were identical to our 
reference values. 
The data of the current patient group are com- 
pared with our reference data in Table III. 
In vitro experiments 
Effect of SNP on CHso (classic and alternate path- 
ways) measured in the serum of seven healthy subjects- 
(Fig. 2). In the presence of SNP, we observed in all 
sera a dose-dependent reduction of the complement 
hemolytic activity as measured by CHso. The inhibitory 
effect of SNP on the alternate pathway occurred at a 
concentration that was three times less than the inhib- 
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itory concentration  the classic pathway (50% inhib- 
itory concentration f SNP on CHs0, 4.2 _+ 0.8 mmol/L 
(mean +_ SD) and 14.0 _+ 2.88 mmol/L for the alter- 
nate pathway and classic pathway, respectively). 
Effect of photodegraded SNP on CHso measured in 
the same sera. In comparison with the data shown 
before, the 50% inhibitory concentration of SNP on 
the available CHs0 decreased to 0.2 _+ 0.02 mmol/L 
(mean +_ SD) for the alternate pathway (p < 0.001) 
and to 2.7 _+ 0.3 mmol/L for the classic pathway (p < 
0.001). Table IV summarizes the influence of non- 
degraded and photodegraded SNP on CHs0. 
Effect of the preincubation time with photode- 
graded SNP (0.6 mmol/L) on CHso (classic path- 
way) measured in the serum of six healthy subjects 
(Fig. 3). We observed in all sera a time-related 
decrease in CH50 according to the period of prein- 
cubation with a suboptimal concentration of SNP of 
0.6 mmol/L. 
Effect of SNP on zymosan-induced C3-conversion 
measured in the serum of five healthy subjects (Fig. 4). 
C3d averaged 4.3 +_ 0.8 txg/ml (mean _+ SD) in the 
sera in which complement activation was blocked 
with ethylenediaminetetraacetic acid (10 mmol/L). 
In contrast, C3d increased to 22.8 _+ 5.1 ixg/ml (p < 
0.001) in control tubes in which sera were supple- 
mented with magnesium-containing alternate path- 
way buffer, displaying an alternate pathway-induced 
C3 conversion caused by contact between serum and 
plastic surfaces. Addition of zymosan further in- 
creased C3d levels to 29.7 _+ 5.0 txg/ml (p < 0.001). 
The presence of SNP (8 retool/L) for 1 hour at 37 ° C 
in sera incubated in plastic tubes significantly re- 
duced C3d levels after zymosan addition, to a value 
of 17.0 _+ 4.0 tzg/ml (p < 0.0001). This value also was 
significantly ower than the C3d value of the control 
sera (p < 0.001). 
Effect of potassium ferrocyanide (2 mmol/L) and 
potassium cyanide (2 mmol/L) on CHso measured in the 
serum of six healthy subjects. The SNP metabolites 
ferrocyanide and cyanide were not able to produce any 
inhibitory effect of SNP on CHs0 (data not shown). 
Comparative ffect of nonphotodegraded SNP (1 
mmol/L), nitroglycerin (1 mmol/L), and isosorbide 
dinitrate (1 mmol/L) on CHso (alternate pathway) 
measured in the serum of six healthy subjects (Fig. 5). 
CHs0 of the control sera was 74 + 10 U/L (mean _+ 
SD). In comparison, CHs0 of the sera treated with 
different vasodilators was in all cases reduced and 
reached 50 _+ 10 U/L for SNP (p < 0.05), 55 + 11 
U/L for nitroglycerin (p < 0.05), and 54 + 11 U/L 
for isosorbide dinitrate (p < 0.05). 
Table III. Comparative data analysis between 
patients treated with SNP and patients not treated 
with SNP 
With SNP Without SNP 
Variables (n = 16) (n = 29) p Value 
Age (mo) 6-84, 29 3-213, 40 NS 
(range, mean) 
CPB (rain) 35-273, 82 31-152, 72 NS 
(range, mean) 
ACC (rain) 29-124, 63 7-105, 56 NS 
(range, mean) 
CCA (min) 6-59, 46 6-60, 44 NS 
(range, mean) (n = 12) (n = 18) 
MSOF (n) 2 8 0.17 
Deaths (n) 3 4 NS 
C4 (mg/dL) 
T~ 19.8 ± 8.3 21.6 - 8.0 NS 
T 2 16.2 + 6.8 18.2 _+ 6.0 NS 
T3 9.9 _+ 3.3 9.5 ± 3.3 NS 
T 6 11.8 ± 4.3* 11.4 ± 3.5 NS 
C3d/C3 
T a 0.75 -+ 0.36 0.78 -+ 0.33 NS 
Y 2 0.65 -+ 0.34 0.81 ± 0.46 NS 
T 3 0.61 ± 0.34 0.77 -+ 0.37 NS 
T 6 1.11 -+ 0.45* 1.52 -+ 0.59 <0.05:~ 
C5a (~g/L) 
T a 8.6 ± 4.4* 18.0 _+ 11.8 <0.0055 
WBC (× 109/L) 
T 1 6.8 -+ 2.2 7.7 -+ 2.5 NS 
T 2 7.2 -+ 2.1 8.3 + 2.1 NS 
T 3 3.3 -+ 2.3 4.3 + 5.7 NS 
Y 4 2.8 -+ 1.5 4.6 + 2.3 <0.025 
T~ 3.7 -+ 3.3 7.1 ± 6.1 <0.055 
T 6 11.3 ± 5.9* 14.5 -+ 8.1 NS 
PN (× 109/L) 
T~ 3.3 _+ 2.2 3.7 + 1.5 NS 
T 2 3.4 + 1.7 4.3 ± 0.67 NS 
T3 1.3 ± 0.6 1.7 _+ 0.9 NS 
T 4 1.0 _+ 0.9 2.2 _+ 1.5 <0.055 
T5 1.8 ± 2.6 2.7 +_ 1.8 NS 
T 6 7.8 ± 4.4* 8.7 _+ 3.0 NS 
Elastase (/xg/L) 
T3 106 ± 59 79 _+ 37 NS 
T 6 418 ± 244* 355 +_ 245 NS 
SNP. sodium nitroprusside; CPB, duration of cardiopulmonary b pass; 
ACC, duration of aortic crosselamping; CCA, duration of cardiocirculatory 
arrest; MSOF, multiple system organ failure; WBC, white blood cells; PN, 
peripheral neutrophils; NS, not significant. For sample times 1, 2, 3, 4, 5, 
and 6, see Table n. Biologic results are expressed by the mean + SD. 
*n - 15. 
tX 2 analysis with Yates' correction. 
:~Mann-Whitney U test. 
Discussion 
The clinical observations of this study suggest that 
SNP influences CPB-induced complement activa- 
tion. These patients treated with SNP had signifi- 
cantly lower C3-conversion and C5a liberation than 
did patients belonging to our previous group, who 
were not treated with SNP. 13 In the current study, as 
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Fig. 2. Effect of increasing concentrations of SNP on CHs0 (n = 7). Results are expressed by the mean _+ 
SEM. The 50% inhibitory concentration CHs0 for the classic (CP) and the alternate (AP) pathways are 
indicated by the projected lines. 
Table IV. Effect of light-degradation on the 50% 
inhibitory concentration of SNP on the available 
CHso, by the classic and the alternate pathways 
50% Inhibitory concentration 
on CHso (rnmol/L) 
Nonphotodegraded Photodegraded p 
SNP SNP Value 
Classic pathway 14.0 _+ 2.88 2.7 _+ 0.3 <0.001" 
Alternate pathway 4.2 + 0.8 0.2 _+ 0.02 <0.001" 
*Mann-Whitney U test. 
in previous works, 8' 11, 13 C4 levels were not signifi- 
cantly modified during CPB. The influence of SNP 
on the classic pathway of the complement cascade 
can therefore not be fully evaluated here. The 
leukocyte traffic during the rewarming period, but 
not after protamine administration, was affected by 
the treatment with SNP, inasmuch as the leukocyte 
count was significantly lower in the current patient 
group than in our reference group. Because leuko- 
cyte count during the rewarming period of CPB 
depends on the number of cells trapped in the lungs 
and also on the number of cells being demarginated 
at the same time owing to restoration of pulmonary 
flow,6, 28 the lower leukocyte count we measured in 
our patients treated with SNP could theoretically be 
explained in two opposite directions, namely higher 
intrapulmonary leukocyte trapping or lesser leuko- 
cyte mobilization. The net increase of leukocyte 
mobilization after protamine administration leading 
to similar counts of circulating leukocytes and leu- 
kocyte elastase release in our patients treated with 
SNP and in those not treated with SNP suggests the 
participation of complement-independent factors of 
leukocyte stimulation, such as rewarming of the 
patient 28 and other chemotactic mediators liberated 
in response to CPB. 29 
To verify the hypothesis of the complement- 
inhibiting effect of SNP and to investigate its mech- 
anism of action, we conducted a series of in vitro 
experiments in our laboratory. These showed that 
SNP inhibits complement activation by both the 
classic and the alternate pathways, and that this 
inhibition is dose-dependent. Our experiments 
clearly show an inhibitory effect on the C3 to C9 
steps of the complement cascade activated by the C3 
convertase, independent of the path of initiation 
(classic or alternate), the effect of SNP on the 
alternate pathway occurring at a concentration that 
was three times less than the inhibitory concentra- 
tion on the classic pathway. However, this difference 
must be interpreted with caution because it could be 
related to our experimental methods: activation of 
the alternate pathway measured with rabbit red cell 
hemolysis occurs with about en times less efficiency 
than the classic pathway-induced hemolysis of sen- 
sitized sheep red cells, thus involving much less 
generation of C3 convertase. With similar sensitivity 
to inhibitory conditions, C3 convertase generation 
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Fig. 3. Effect of preincubation with photodegraded SNP (0.6 mmol/L) on CHso by activation of the classic 
pathway (black circles). Results are expressed by the mean _+ SEM. The open circle represents he control 
sera (n = 6). 
or activity induced by the alternate pathway would 
be more easily inhibited than C3 convertase induced 
by the classic pathway. Because the zymosan-in- 
duced C3d generation is inhibited by SNP in buffer 
conditions allowing the alternate pathway to be 
activated exclusively, the C3 convertase of the alter- 
nate pathway must be one of the targets for this 
inhibitory effect. Specific site(s) of action of SNP on 
the complement cascade remain(s) to be elucidated 
in further studies. 
Photodegradation f SNP and preincubation of 
the sera tested with SNP increased the inhibitory 
effect on the complement lytic activity in vitro, 
suggesting the role of a metabolite of SNP respon- 
sible for this effect. We excluded the SNP metabo- 
lites ferrocyanide and cyanide for this role. SNP 
containing a nitrogen in a low oxidative state re- 
leases nitric oxide by a nonenzymatic mechanism 
involving a simple one-electron reduction. 3° Light 
exposure of SNP, as well as a variety of reducing 
agents, induces nitric oxide release from SNP in this 
way. 31 We suggest hat the inhibitory effect of SNP 
on the complement lytic activity measured in vitro 
and on the C3 conversion and CSa liberation mea- 
sured in vivo is mediated by nitric oxide. This 
contention is supported by the similar inhibitory 
effect on the complement hemolytic activity that we 
observed in vitro with nitroglycerin and isosorbide 
dinitrate, which are other vasodilators releasing 
nitric oxide by mechanisms involving an enzymatic 
reactionY To the best of our knowledge, this is the 
first report on the anticomplementary p operties of 
nitric oxide demonstrated in vitro and in vivo, 
increasing the number of its previously described 
properties. 32-34 
In our clinical observations, complement activa- 
tion during CPB and after protamine administration 
was reduced in patients treated with SNP but not 
totally abolished. It must be noted that the initial 
purpose of this clinical study was not to investigate 
the unexpected inhibitory effect of SNP on comple- 
ment activation in patients undergoing cardiac op- 
erations. SNP was administered as a vasodilator, 
and its nonuniform dosage was adapted to each 
hemodynamic situation. The dose-dependency of 
the anticomplementary effect of SNP demonstrated 
in vitro could explain the attenuation but not the 
total inhibition of complement activation in our 
patients. In our in vitro experiments using hemolytic 
tests (CHs0) for the study of the inhibitory effect of 
SNP on complement activation, relatively large 
doses of SNP were necessary to show a positive 
effect. These concentrations (ranging from 0.2 to 1 
mmol/L) correspond to about 60 to 300 mg/L, the 
30- to 100-fold amount of SNP infused to a child 
receiving 2/xg/kg per minute over 1 hour. 
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Fig. 4. C3d generation measured in plastic tubes containing ethylenediaminetetraacetic acid (EDTA) is 
significantly inhibited compared with C3d generation i  plastic tubes where the alternate pathway is 
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serum (asterisk) (p < 0.001). SNP significantly limits C3d generation caused by zymosan addition (double 
asterisks) (p < 0.0001), reducing C3d levels below the value measured in the control serum (p < 0.001) 
(paired t test). Results are expressed as mean _+ SEM 0z = 5). 
Hemolytic tests leading necessarily to the pres- 
ence of free hemoglobin inactivating nitric oxide 3~ 
introduce a negative bias in the study of the dose- 
response relationship of SNP as an anticomplemen- 
tary substance. Efficient in vivo concentrations of
SNP are probably far lower than those necessary to 
produce an equivalent effect in vitro, but at present 
the dose-response r lationship of the anticomple- 
mentary effect of SNP would be difficult o establish. 
Indeed, liberation of nitric oxide from SNP in vivo is 
a dynamic and nonlinear process depending on the 
ubiquitous presence of several reducing (activating 
nitric oxide release) or oxidizing (inhibiting nitric 
oxide release) agents. 31 Their concentrations vary 
from tissue to tissue and are necessarily different in 
the healthy subject and in the patient undergoing 
CPB; the latter is subjected to an inflammatory 
process associated with the extracellular liberation 
of substances able to locally inhibit or enhance the 
generation or the action of nitric oxide, as do, 
among others, free hemoglobin and the superoxide 
anion.31, 35 Furthermore, in our clinical model in- 
volving profound hypothermia, the temperature de- 
pendence of SNP reduction, which was clearly dem- 
onstrated in vitro in a range of temperatures 
between 15 ° and 30 ° C, 31 could certainly negatively 
influence nitric oxide release. 
It was recently suggested in an animal model that 
SNP--by nitric oxide release--attenuates r vascu- 
larization lung injury by inhibition of pulmonary 
neutrophil influx. 36 It is possible that attenuated C3 
conversion and especially C5a liberation has been 
responsible for some of the SNP effects reported in 
that study. Moreover, endogenous nitric oxide has 
been demonstrated to inhibit leukocyte adhesion by 
a mechanism involving the regulation of the leuko- 
cyte adhesion molecules. 37 More recently, similar 
effects were shown with a novel nitric oxide donor. 38 
Thus both exogenous and endogenous nitric oxide 
inhibit leukocyte adherence to the endothelium, and 
this effect is protective in experimental models involv- 
ing ischemia nd reperfusion and thus could be bene- 
ficial in the treatment of patients undergoing cardiac 
operations. Whether SNP had influenced periopera- 
tive leukocyte adhesion in our patients cannot be 
definitively assessed here, as discussed earlier. 
The clinical relevance of attenuated complement 
activation by SNP could not be clearly demonstrated 
in the clinical part of our study because, although 
multiple system organ failure became less prevalent 
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Fig. 5. Comparative effect of nonphotodegraded SNP (1 mmol/L), nitroglycerin (NTG) (1 mmol/L), and 
isosorbide dinitrate (ISDN) (1 mmol/L) on CH50 by the alternate pathway. Similar significant reduction of 
CHso is seen in all cases of sera treated with nitrovasodilators compared with the control sera (p < 0.05, 
Wilcoxon test) (n = 6). Results are expressed as mean _+ SEM (n = 6). 
in patients who received SNP than in the untreated 
patient group, the difference was not statistically 
significant. The indubitable demonstration of the 
clinical benefit of administering SNP during CPB 
needs a prospective randomized study on a much 
larger series, which we will not be able to conduct 
for ethical reasons. In our overall experience, mul- 
tiple organ system failure became significantly less 
prevalent after SNP was introduced in our CPB 
protocol. 39 Thus we believe we cannot randomize to 
a non-SNP group. At present, SNP has numerous 
advantages over other intravenous nitric oxide do- 
nors available for clinical use. 25 Its pharmacologic 
and long known hemodynamic properties induce 
systemic and also pulmonary vasodilation. 4° SNP 
also was recently demonstrated to induce left ven- 
tricular relaxation and to improve left ventricular 
diastolic function in adults. 41 Furthermore, in chil- 
dren undergoing cardiac operations it improved the 
postoperative cardiac index and did not cause re- 
lated thiocyanate toxicity. 42' 43 Last, SNP displays a 
low cost efficiency ratio. 
In conclusion, we showed in vitro that SNP inhib- 
its, most probably by nitric oxide release, comple- 
ment system activation initiated through either the 
alternate or the classic pathway. In our clinical 
study, CPB-induced C3 conversion and C5a libera- 
tion were less in patients receiving SNP for periop- 
erative vasodilation than in patients who were not 
treated with SNP. The anticomplementary proper- 
ties of SNP, combined with its hemodynamic effects, 
suggests that SNP is the vasodilator of choice for 
patients undergoing cardiac operations. 
We thank K. Buro for advice in statistical analysis and 
I. Sprangers, H. Collet, and H. Schreyen for technical 
assistance. 
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